Memorial Sloan Kettering Cancer Center investigators and collaborators have tested rezatapopt, an oral p53 reactivator designed for tumors with TP53 Y220C, and observed antitumor activity across ...

Schematic illustrating the effects of p53C and M237I in driving the conversion of p63C and p73C droplets into amyloid aggregates at physiologically relevant temperatures. Heparin prevents the ...

p53 is one of the most important proteins in cancer biology. Often referred to as a "guardian of the genome," p53 becomes activated in response to various cellular stressors like DNA damage. Its ...

However, its significance extends beyond cancer to the pathogenesis of autoimmune diseases. In addition to its classic effects on the cell cycle and ...

A protein famed among scientists and clinicians for its ability to suppress the development of many types of tumors may just be moonlighting as a cancer fighter, a recent study by researchers at ...

Researchers have elucidated the role of the p53 gene in ulcerative colitis. The study suggests a potential new drug target to stop disease progression to cancer. Researchers in the lab of Michael ...

A new research paper was published in Oncotarget, Volume 16, on February 18, 2025, titled "Robust p53 phenotypes and prospective downstream targets in telomerase-immortalized human cells." Researchers ...

One of the biggest challenges in cancer immunotherapy may not be that immune cells are too weak, but that some tumors give them too little to see. New research from Dana-Farber Cancer Institute ...

PMV Pharma is preparing to file for approval of its oral p53 protein reactivator drug rezatopopt in the first quarter of 2027, after reporting positive results in a phase 2 trial in ovarian cancer.